Syros Pharmaceuticals, Inc.
SYRSDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tamibarotene | Phase 2 | Acute Myeloid Leukemia | - | - |
Frequently asked questions
What is in Syros Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Syros Pharmaceuticals, Inc.'s (SYRS) pipeline across Phase 2. Its lead program is Tamibarotene (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Syros Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Syros Pharmaceuticals, Inc. (SYRS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SYRS biotech catalysts?→
Add SYRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Syros Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.